Clarity Pharmaceuticals (CU6) H1 2026 earnings summary

Executive summary

• Loss for the half-year ended 31 December 2025 was $55.7 million, up from $23.5 million in the prior year, driven by a significant increase in R&D expenditure to $50.5 million as clinical trial activities expanded.

• Cash and term deposits totaled $226.2 million at period end, bolstered by a $203 million capital raise at a premium to market price, positioning the group to support ongoing programs.

• The company advanced its pipeline with multiple late-stage clinical trials in prostate cancer and neuroendocrine tumours, and expanded its discovery platform targeting additional cancer indications.

Financial highlights

• Net loss for the half-year was $55.7 million (2024: $23.5 million loss), reflecting increased R&D and commercialisation expenses.

• R&D expenses rose to $50.5 million (2024: $28.6 million), and corporate/commercialisation expenses to $12.0 million (2024: $5.9 million).

• Cash and cash equivalents at 31 December 2025 were $70.5 million, with term deposits of $155.8 million.

• Net assets increased to $232.8 million from $90.2 million at 30 June 2025.

• Basic and diluted loss per share was 15.3 cents (2024: 7.4 cents).

Outlook and guidance

• The board believes the group is well placed to support its programs throughout FY2026, with sufficient cash and financial assets to meet foreseeable expenditure commitments.

• Recruitment for pivotal Phase III trials (CLARIFY, AMPLIFY, and SARTATE) is ongoing, with regulatory submissions targeted upon completion.